Lixte Biotechnology Holdings 過去の業績

過去基準チェック /06

Lixte Biotechnology Holdingsの収益は年平均-28.3%で減少しているが、Biotechs業界はgrowingで7.7%年平均の収益となった。

主要情報

-28.3%

収益成長率

-18.4%

EPS成長率

Biotechs 業界の成長	-14.6%
収益成長率	n/a
株主資本利益率	-228.2%
ネット・マージン	n/a
前回の決算情報	30 Jun 2023

Recent updates

収支内訳

Lixte Biotechnology Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:8640 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Jun 23	-6	5	1
31 Mar 23	-6	5	1
31 Dec 22	-6	5	1
30 Sep 22	-7	5	2
30 Jun 22	-6	5	2
31 Mar 22	-7	5	2
31 Dec 21	-7	5	2
30 Sep 21	-6	4	1
30 Jun 21	-6	4	2
31 Mar 21	-5	3	2
31 Dec 20	-3	2	1
30 Sep 20	-3	2	1
30 Jun 20	-2	1	1
31 Mar 20	-2	2	1
31 Dec 19	-2	2	1
30 Sep 19	-2	2	1
30 Jun 19	-2	2	0
31 Mar 19	-2	2	0
31 Dec 18	-2	2	0
30 Sep 18	-2	2	0
30 Jun 18	-2	1	0
31 Mar 18	-2	1	0
31 Dec 17	-2	1	0
30 Sep 17	-2	1	1
30 Jun 17	-2	2	0
31 Mar 17	-2	2	1
31 Dec 16	-2	1	1
30 Sep 16	-2	1	1
30 Jun 16	-2	1	2
31 Mar 16	-2	1	2
31 Dec 15	-3	1	2
30 Sep 15	-3	1	2
30 Jun 15	-3	1	1
31 Mar 15	-3	1	1
31 Dec 14	-3	1	1
30 Sep 14	-3	1	1
30 Jun 14	-2	1	1
31 Mar 14	-2	1	1
31 Dec 13	-1	0	1
30 Sep 13	-1	1	1
30 Jun 13	-3	1	1
31 Mar 13	-3	1	1
31 Dec 12	-4	1	1

質の高い収益: 8640は現在利益が出ていません。

利益率の向上: 8640は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 8640は利益が出ておらず、過去 5 年間で損失は年間28.3%の割合で増加しています。

成長の加速: 8640の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 8640は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: 8640は現在利益が出ていないため、自己資本利益率 ( -228.24% ) はマイナスです。

Lixte Biotechnology Holdings 過去の業績

過去基準チェック /06

主要情報

最近の業績更新

Recent updates

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Nov 27, 2023

Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes

LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol

LIXTE Biotechnology Announces 1-for-10 Reverse Stock Split to Bring it into Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Lixte Biotechnology Holdings, Inc. Announces Recently Published Independent Research Reveals New Mechanisms

Lixte Biotechnology Holdings, Inc. Promotes Eric Forman to Vice President and Chief Operating Officer

LIXTE Biotechnology Holdings, Inc. Announces Spanish Agency for Medicines and Health Products Authorized Phase 1b/Randomized Phase 2 Study of LB-100

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Oct 07, 2022

Lixte Biotechnology Holdings, Inc. Appoints Bastiaan Van Der Baan as Independent Director

Lixte Biotechnology Holdings, Inc. Appoints Bas Van Der Baan to Its Board of Directors

Lixte Biotechnology Holdings, Inc. Announces Appointment of Professor René Bernards to its Board of Directors

Philip Palmedo Not to Stand for Re-Election as Director of Lixte Biotechnology Holdings, Inc

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Lixte Biotechnology Holdings, Inc. Announces Enrollment Has Resumed in National Cancer Institute’s Trial to Determine Ability of Lixte Compound LB-100 to Enter Recurrent, Malignant Brain Tumors

LixteBiotechnology Holdings, Inc.'s Pre-Clinical Research Demonstrates Inhibition of Protein Phosphatase 2A with LB-100 Combined with the Experimental Drug, Vosoritide

Lixte Biotechnology Holdings, Inc.(NasdaqCM:LIXT) dropped from Russell 3000E Value Index

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Independent Director has left the company

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

Lixte Biotechnology Holdings 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Nov 27, 2023

Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes

LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol

LIXTE Biotechnology Announces 1-for-10 Reverse Stock Split to Bring it into Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Lixte Biotechnology Holdings, Inc. Announces Recently Published Independent Research Reveals New Mechanisms

Lixte Biotechnology Holdings, Inc. Promotes Eric Forman to Vice President and Chief Operating Officer

LIXTE Biotechnology Holdings, Inc. Announces Spanish Agency for Medicines and Health Products Authorized Phase 1b/Randomized Phase 2 Study of LB-100

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Oct 07, 2022

Lixte Biotechnology Holdings, Inc. Appoints Bastiaan Van Der Baan as Independent Director

Lixte Biotechnology Holdings, Inc. Appoints Bas Van Der Baan to Its Board of Directors

Lixte Biotechnology Holdings, Inc. Announces Appointment of Professor René Bernards to its Board of Directors

Philip Palmedo Not to Stand for Re-Election as Director of Lixte Biotechnology Holdings, Inc

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Lixte Biotechnology Holdings, Inc. Announces Enrollment Has Resumed in National Cancer Institute’s Trial to Determine Ability of Lixte Compound LB-100 to Enter Recurrent, Malignant Brain Tumors

LixteBiotechnology Holdings, Inc.'s Pre-Clinical Research Demonstrates Inhibition of Protein Phosphatase 2A with LB-100 Combined with the Experimental Drug, Vosoritide

Lixte Biotechnology Holdings, Inc.(NasdaqCM:LIXT) dropped from Russell 3000E Value Index

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Independent Director has left the company

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06